NCT07213440 Identification of Early Markers for ALS
| NCT ID | NCT07213440 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut National de la Santé Et de la Recherche Médicale, France |
| Condition | Amyotrophic Lateral Sclerosis (ALS) |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-09-30 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2024-09-30 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Although several molecules have been proposed as biomarker candidates, a clinically established signature for an early or even premotor diagnosis of ALS is not available. Due to the already advanced, disease stage at the time of diagnosis as well as rapid disease progression, an early diagnosis is mandatory for efficacious disease-modifying therapies. In this project, the investigators will develop a clinical molecular fingerprint of PGMC that will provide insight into the molecular pathogenesis of ALS and allow earlier diagnosis.
Eligibility Criteria
Inclusion Criteria: FIRST GROUP: Premotor gene mutation carriers (PGMC): * 18-90 years of age * Provision of a written informed consent * Affiliation with a social security scheme or beneficiary of such a scheme * Diagnosed by a clinically certified laboratory with a disease- causing mutation in a known ALS gene by predictive genetic testing * No symptoms of motor neuron disease explainable otherwise than by mutation in a known ALS gene SECOND GROUP: Control subjects to premotor gene mutation carriers (CTR): * 18-90 years of age * Provision of a written informed consent * Affiliation with a social security scheme or beneficiary of such a scheme * No known genetic mutation and no known ALS disease in close family * No diagnosed motor-neuron disease THIRD GROUP: ALS (EALS) / ALS mimics (MIM) * 18-90 years of age * provision of a written informed consent * affiliation with a social security scheme or beneficiary of such a scheme * Patients with pure motor symptom or early ALS (EALS) or ALS mimics (MIM) EALS are patients with pure motor symptom / early motor symptoms of ALS, including those, where the diagnosis of ALS can already be made. These may be patients who meet the following criteria: According to El Escorial criteria : patients who can be classified as possible ALS or those who show upper motor neuron (UMN) signs only or lower motor neuron (LMN) signs only, so that classification as possible ALS is also not possible. Symptoms should not persist for more than 12 months. According to Gold Coast criteria: Patients who do not fulfill the criterion of temporal progression or patients who only show UMN signs or only LMN signs in one region and thus do not fulfill the diagnostic criteria of ALS. Exclusion Criteria: * Inability to express consent to the study * Persons subject to a judicial safeguard measure, under guardianship or curatorship. * Linguistic incapacity or psychic refusal to read the information. * Pregnant women * Foreseen inability to attend scheduled visits * Persons refusing to take one of the following samples: Acquisition of blood samples, Acquisition of tear fluid samples, Acquisition of urine sample
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07213440 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Amyotrophic Lateral Sclerosis (ALS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07213440 currently recruiting?
Yes, NCT07213440 is actively recruiting participants. Contact the research team at philippe.corcia@univ-tours.fr for enrollment information.
Where is the NCT07213440 trial being conducted?
This trial is being conducted at Tours, France.
Who is sponsoring the NCT07213440 clinical trial?
NCT07213440 is sponsored by Institut National de la Santé Et de la Recherche Médicale, France. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.